Skip to main content

Table 2 Patient characteristics during ICU stay according to study group and aspergillosis status based on Blot definition

From: Invasive pulmonary aspergillosis among intubated patients with SARS-CoV-2 or influenza pneumonia: a European multicenter comparative cohort study

 

SARS-CoV-2 pneumonia

n = 566

Influenza pneumonia

n = 481

No putative IPA, or colonization

(n = 543)

Aspergillus colonization

(n = 9)

Putative IPA

(n = 14)

No putative IPA, or colonization

(n = 432)

Aspergillus colonization

(n = 20)

Putative IPA

(n = 29)

Prone positioning

363/543 (66.9)

6/8 (75.0)

12/14 (85.7)

126/432 (29.2)

8/19 (42.1)

17/29 (58.6)

ECMO

58/542 (10.7)

0/9 (0.0)

2/14 (14.3)

49/432 (11.3)

5/19 (26.3)

6/28 (21.4)

Ventilator-associated lower respiratory tract infections

271/543 (49.9)

7/9 (77.8)

7/14 (50.0)

127/432 (29.4)

7/20 (35.0)

12/29 (41.4)

Antimicrobial treatment duration, days†

12 (7 to 18)

16 (10 to 19)

18 (8 to 20)

9 (6 to 16)

21 (12 to 28)

17 (9 to 27)

Corticosteroids

188/517 (36.4)

3/9 (33.3)

10/14 (71.4)

161/426 (37.8)

8/20 (40.0)

12/28 (42.9)

Hydrocortisone

55/512 (10.7)

2/9 (22.2)

2/14 (14.3)

92/424 (21.7)

7/20 (35.0)

7/28 (25.0)

Dexamethasone

44/512 (8.6)

0/9 (0.0)

4/14 (28.6)

1/424 (0.2)

0/20 (0.0)

0/28 (0.0)

Methylprednisolone

85/512 (16.6)

1/9 (11.1)

4/14 (28.6)

67/424 (15.8)

1/20 (5.0)

5/28 (17.9)

Highest daily dose, mg‡

100 (50 to 133)

50 (50 to 100)

100 (50 to 133)

50 (50 to 100)

50 (50 to 100)

63 (50 to 100)

28-day outcomes

      

Mechanical ventilation duration, days

14 (8 to 22)

23 (12 to 28)

23 (17 to 28)

9 (5 to 18)

24 (11 to 28)

21 (12 to 28)

Ventilator-free days

6 (0 to 16)

0 (0 to 0)

1 (0 to 2)

13 (0 to 21)

1 (0 to 12)

0 (0 to 3)

ICU length of stay, days

17 (12 to 27)

28 (13 to 28)

25 (19 to 28)

13 (8 to 25)

28 (17 to 28)

25 (15 to 28)

ICU-free days

0 (0 to 12)

0 (0 to 0)

0 (0 to 0)

5 (0 to 18)

0 (0 to 2)

0 (0 to 0)

ICU mortality

154/543 (28.4)

4/9 (44.4)

5/14 (35.7)

111/432 (25.7)

3/20 (15.0)

11/29 (37.9)

28-day mortality

156/543 (28.7)

4/9 (44.4)

5/14 (35.7)

118/432 (27.3)

3/20 (15.0)

11/29 (37.9)

  1. Values are as n/N (%) or median (interquartile range). †18 missing values (SARS-CoV-2, n = 15; influenza, n = 3); ‡8 missing values (SARS-CoV-2, n = 4; influenza, n = 4)
  2. Data are collected until day 28 or discharge of ICU
  3. ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit
Back to article page

Critical Care

ISSN: 1364-8535